PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration ...

Utilizing one-week price change and the monthly percentage ... Momentum investors should take note of this Medical stock. PFE has a Momentum Style Score of B, and shares are up 5.2% over the ...

Is Pfizer stock a buy or a sell after the company rallied on its mixed outlook for 2025? Is PFE stock a buy or a sell right now? All It Takes Is $3,500 Invested in Each of These 3 Dow Dividend ...

AI stocks are stealing the spotlight today as the appetite for these services continues to gain traction globally.

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Pfizer is expected to post earnings of $0.49 ...

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed ...